Thrombosis and haemostasis, where clinical and basic science meet.

Thromb Haemost

Center for Molecular and Vascular Biology, University of Leuven, Herenstraat 49, B 3000 Leuven, Belgium.

Published: July 2007

Download full-text PDF

Source

Publication Analysis

Top Keywords

thrombosis haemostasis
4
haemostasis clinical
4
clinical basic
4
basic science
4
science meet
4
thrombosis
1
clinical
1
basic
1
science
1
meet
1

Similar Publications

Background: Disseminated intravascular coagulation (DIC) is a potentially fatal condition which is always secondary to an underlying disorder with abruption being the most common cause in obstetrics.Our study analysed the modified International Society of Thrombosis and Haemostasis DIC score for prediction of DIC in cases of abruptio placentae. Additionally, we correlated the score with severity of abruption to optimize its use in limited resource settings.

View Article and Find Full Text PDF

Fibrin film on clots is increased by haematocrit but reduced by inflammation: implications for platelets and fibrinolysis.

J Thromb Haemost

January 2025

Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

Background: Blood clot formation, triggered by vascular injury, is crucial for haemostasis and thrombosis. Blood clots are composed mainly of fibrin fibres, platelets and red blood cells (RBCs). Recent studies show that clot surface also develops a fibrin film, which provides protection against wound infection and retains components such as RBCs within the clot.

View Article and Find Full Text PDF

Adequate secondary prevention in survivors of intracerebral hemorrhage (ICH) who also have atrial fibrillation (AF) is a long-standing clinical dilemma because these patients are at increased risk of recurrent ICH as well as of ischemic stroke. The efficacy and safety of oral anticoagulation, the standard preventive medication for ischemic stroke patients with AF, in ICH patients with AF are uncertain. PRESTIGE-AF is an international, phase 3b, multi-center, randomized, open, blinded end-point assessment (PROBE) clinical trial that compared the efficacy and safety of direct oral anticoagulants (DOACs) with no DOAC (either no antithrombotic treatment or any antiplatelet drug).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!